Long-term efficacy and safety of quetiapine in treatment-refractory schizophrenia: A case report

International Journal of Psychiatry in Clinical Practice

Volumn 4, Issue 1, 2000, Pages 77-80

  Reznik, I ^a,b   Benatov, R ^a   Sirota, P ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b ABARBANEL MENTAL HEALTH CENTER   (Israel)

Author keywords

Atypical antipsychotics; Quetiapine; Schizophrenia; Seroquel; Treatment resistance

Indexed keywords

QUETIAPINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; LONG TERM CARE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; SCHIZOPHRENIA; TREATMENT PLANNING;

EID: 0034041789     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500050518442     Document Type: Article

References (17)

1. Andersson C, Chakos M, Mailman R, Lieberman J (1998) Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. Psychiatr Clin North Am 21: 151-79.
2. Hirsch SR, Link CGG, Goldstein JM, Arvanitis LA (1996) ICI 204,636: a new atypical antipsychotic drug. Br J Psychiatry 168 (Suppl 29): 45-56.
3. Fabre LF Jr, Arvanitis L, Pultz J et al (1997) ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 17: 366-78.
4. Borison RL, Arvanitis LA, Miller BG (1996) ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16: 158-69.
5. Arvanitis LA, Miller BG (1997) Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233-46.
6. Reznik I, Benatov R, Sirota P (1996) Seroquel in a resistant schizophrenic with negative and positive symptoms (in Hebrew). Harefuah 130: 675-77.
7. Arvanitis LA, Rak IW (1997) The long-term efficacy and safety of quetiapine. In: New Research Program and Abstracts of the 150 Annual Meeting of the American Psychiatric Association, May 1997, San Diego, CA. (Abstract NR230). APA, Washington, DC.
8. Meats P (1997) Quetiapine (Seroquel); an effective and well-tolerated atypical antipsychotic. Int J Psych Clin Pract 1: 231-9.
9. Goldstein JM (1998) Inaccurate information on quetiapine (letter). J Clin Psychiatry 59: 687.
10. Maeda H, Kotorii T, Nakamura J, Uchimura N (1998) Clinical evaluation of quetiapine (ICI 204,636), a novel antipsychotic agent, in treatment-resistant schizophrenic patients. In: Proceedings of XXI CINP Congress, Glasgow, 12-16 July 1998; The Scientific Program and Book of Abstracts. Abstract: PT 07099.
11. Kane JM, Honigfeld G, Singer J, Meltzer HY and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789-96.
12. Marder SR (1996) Management of treatment-resistant patients with schizophrenia. J Clin Psychiatry 57 (suppl 11): 26-30.
13. King DJ (1998) Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 8: 33-42.
14. Tamminga CA, Lahti AC (1996) The new generation of antipsychotic drugs. Int Clin Psychopharmacol 11 (suppl 2): 73-6.
15. Meltzer HY (1997) Treatment-resistant schizophrenia - the role of clozapine. Curr Med Res Opin 14: 1-20.
16. Stip E (1996) Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy. Can J Psychiatry 41 (suppl 2): S27-S34.
17. Fleischhacker WW, Hummer M (1997) Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimizing outcomes. Drugs 53: 915-29.